Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Beam Therapeutics Inc (Symbol: BEAM) entered into oversold territory, hitting an RSI ...

The technology, which in the past had been limited by size and cost, provides targeted doses of radiation to tumors, ...

The ARKK fund bought 69,011 shares of CRISPR Therapeutics AG and 142,713 shares of Beam Therapeutics Inc. Based on the last ...

Beam Therapeutics Inc. (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...

Two Massachusetts researchers are among the recipients of an award known as the “Oscars of Science” for their research in ...

Investor’s Business Daily said that Ark Invest picked up 79,318 shares of Tesla, valued at $17.62 million based on Monday’s ...